I agree that this site is using cookies. You can find further informations here.
X
Takeda, Tatsuaki
36  results:
Search for persons X
?
1

A comparison between the adverse event profiles of patients..:

Takeda, Tatsuaki ; Sugimoto, Shiho ; Matsumoto, Jun...
International Journal of Clinical Pharmacy.  46 (2024)  2 - p. 536-541 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Adverse events of nivolumab plus ipilimumab versus nivoluma..:

Oka, Yurie ; Matsumoto, Jun ; Takeda, Tatsuaki...
International Journal of Clinical Pharmacy.  46 (2024)  3 - p. 745-750 , 2024
Link: https://doi.org/10.1007/..
 
?
3

Adverse Events of Axitinib plus Pembrolizumab Versus Lenvat..:

Matsumoto, Jun ; Iwata, Naohiro ; Watari, Shogo...
European Urology Focus.  9 (2023)  1 - p. 141-144 , 2023
Link: https://doi.org/10.1016/..
 
?
4

Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two ..:

Mitsuboshi, Satoru ; Hamano, Hirofumi ; Kuniki, Yurika...
Annals of Pharmacotherapy.  57 (2023)  11 - p. 1255-1263 , 2023
Link: https://doi.org/10.1177/..
 
?
5

Influence of vasopressin receptor antagonists on triple‐wha..:

Mitsuboshi, Satoru ; Hayakawa, Kenji ; Hamano, Hirofumi...
British Journal of Clinical Pharmacology.  90 (2023)  3 - p. 900-904 , 2023
Link: https://doi.org/10.1111/..
 
?
6

Significance of UGT1A6, UGT1A9, and UGT2B7 genetic variants..:

Matsumoto, Jun ; Nishimoto, Anzu ; Watari, Shogo...
Molecular and Cellular Biochemistry.  478 (2022)  8 - p. 1779-1790 , 2022
Link: https://doi.org/10.1007/..
 
?
7

Drug repositioning of tranilast to sensitize a cancer thera..:

Ochi, Kosuke ; Suzawa, Ken ; Thu, Yin Min...
Cancer Science.  113 (2022)  10 - p. 3428-3436 , 2022
Link: https://doi.org/10.1111/..
 
?
8

YES1 as a Therapeutic Target for HER2-Positive Breast Cance..:

Fujihara, Miwa ; Shien, Tadahiko ; Shien, Kazuhiko...
International Journal of Molecular Sciences.  22 (2021)  23 - p. 12809 , 2021
Link: https://doi.org/10.3390/..
 
?
9

YES1 activation induces acquired resistance to neratinib in..:

Takeda, Tatsuaki ; Yamamoto, Hiromasa ; Suzawa, Ken...
Cancer Science.  111 (2020)  3 - p. 849-856 , 2020
Link: https://doi.org/10.1111/..
 
?
10

Overcoming epithelial-mesenchymal transition-mediated drug ..:

Ochi, Kosuke ; Suzawa, Ken ; Tomida, Shuta...
Biochemical and Biophysical Research Communications.  529 (2020)  3 - p. 760-765 , 2020
Link: https://doi.org/10.1016/..
 
?
11

Application of amplicon-based targeted sequencing with the ..:

Namba, Kei ; Tomida, Shuta ; Matsubara, Takehiro...
BMC Cancer.  19 (2019)  1 - p. , 2019
Link: https://doi.org/10.1186/..
 
?
12

Acquired resistance mechanisms to afatinib in HER2‐amplifie..:

Yoshioka, Takahiro ; Shien, Kazuhiko ; Takeda, Tatsuaki...
Cancer Science.  110 (2019)  8 - p. 2549-2557 , 2019
Link: https://doi.org/10.1111/..
 
?
13

Therapeutic strategies for afatinib‐resistant lung cancer h..:

Torigoe, Hidejiro ; Shien, Kazuhiko ; Takeda, Tatsuaki...
Cancer Science.  109 (2018)  5 - p. 1493-1502 , 2018
Link: https://doi.org/10.1111/..
 
?
14

Yes1 signaling mediates the resistance to Trastuzumab/Lap a..:

Takeda, Tatsuaki ; Yamamoto, Hiromasa ; Kanzaki, Hirotaka...
PLOS ONE.  12 (2017)  2 - p. e0171356 , 2017
Link: https://doi.org/10.1371/..
 
?
15

Differential Combined Effect of COX Inhibitors on Cell Surv..:

Yagi, Kenta ; Kawasaki, Yoichi ; Nakamura, Hiroko...
Biological and Pharmaceutical Bulletin.  37 (2014)  7 - p. 1234-1240 , 2014
Link: https://doi.org/10.1248/..
 
1-15